Advanced search
Publication Cover
Current Medical Research and Opinion Volume 31, 2015 - Issue 10
Submit an article Journal homepage
486
Views
13
CrossRef citations to date
0
Altmetric
Oncology

Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients

Patrick N. RacsaComprehensive Health Insights, Humana Inc. Louisville, KY, USACorrespondence[email protected]
,
Tyler R. WhismanHumana Inc., Union, KY, USA
&
Karen WorleyComprehensive Health Insights, Humana Inc. Louisville, KY, USA
Pages 1933-1940 | Accepted 07 Aug 2015, Published online: 20 Aug 2015

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Stefano Capri, Camillo Porta, Claudia Condorelli, Eleonora Premoli, Ankur Khare, Manik Kalra, Niraj Modi & Barbara Ratto. (2020) An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. Journal of Medical Economics 23:12, pages 1579-1587.
Read now

Articles from other publishers (12)

Dong Hyuk Kang, Joo Yong Lee, Yunhee Lee & U-Syn Ha. (2023) Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System. BMC Cancer 23:1.
Crossref
Ruggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, Felice Musicco, Paolo Abrate & Alberto Costantini. (2021) Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. Journal of Oncology Pharmacy Practice 28:4, pages 870-883.
Crossref
Deborah R. Kaye, Lauren E. Wilson, Melissa A. Greiner, Lisa P. Spees, Jessica E. Pritchard, Tian Zhang, Craig E. Pollack, Daniel George, Charles D. ScalesJrJr, Chris D. Baggett, Cary P. Gross, Michael S. Leapman, Stephanie B. Wheeler & Michaela A. Dinan. (2022) Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma. Journal of Geriatric Oncology 13:5, pages 614-623.
Crossref
Lisa P. Spees, Stephanie B. Wheeler, Bradford E. Jackson, Christopher D. Baggett, Lauren E. Wilson, Melissa A. Greiner, Deborah R. Kaye, Tian Zhang, Daniel George, Charles D. ScalesJrJr, Jessica E. Pritchard, Michael Leapman, Cary P. Gross & Michaela A. Dinan. (2021) Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine 10:19, pages 6653-6665.
Crossref
Stefania Brozzetti, Simone Bini, Nelide De Lio, Carlo Lombardo & Ugo Boggi. (2020) Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis. BMC Surgery 20:1.
Crossref
Huan Deng, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei & Wenxiong Zhang. (2019) Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC Cancer 19:1.
Crossref
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu & Ya-Chen Tina Shih. (2018) Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review. PharmacoEconomics 37:3, pages 301-331.
Crossref
B. Ya. Alekseev & I. M. Shevchuk. (2018) Pazopanib as first-line therapy for patients with metastatic kidney cancer. Medical Council:10, pages 70-76.
Crossref
Nicholas J. VogelzangSumanta K. PalSameer R. GhateNanxin LiElyse SwallowMiranda PeeplesMiriam L. ZichlinMark K. MeiselbachJose Ricardo PerezNeeraj Agarwal. (2018) Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. Journal of Managed Care & Specialty Pharmacy 24:6, pages 525-533.
Crossref
Nicholas J. Vogelzang, Sumanta K. Pal, Sameer R. Ghate, Elyse Swallow, Nanxin Li, Miranda Peeples, Miriam L. Zichlin, Mark K. Meiselbach, Jose Ricardo Perez & Neeraj Agarwal. (2017) Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Advances in Therapy 34:11, pages 2452-2465.
Crossref
James E. Frampton. (2017) Pazopanib: a Review in Advanced Renal Cell Carcinoma. Targeted Oncology 12:4, pages 543-554.
Crossref
Elizabeth MacLean, Jack Mardekian, Laura A. Cisar, Caroline J. Hoang & James Harnett. (2016) Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib. Journal of Managed Care & Specialty Pharmacy 22:8, pages 979-990.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.